ライフサイエンスコーパス: intrahepatic cholangiocarcinoma

1 % were hepatocellular carcinoma and 20% were intrahepatic cholangiocarcinoma.

2 llular carcinoma with stem cell features and intrahepatic cholangiocarcinoma.

3 a target of transformation and an origin of intrahepatic cholangiocarcinoma.

4 epatocytes in this model as well as in human intrahepatic cholangiocarcinoma.

5 itumor effects in an orthotopic rat model of intrahepatic cholangiocarcinoma.

6 ncreasing in frequency as is that of primary intrahepatic cholangiocarcinoma.

7 ors, several others could be associated with intrahepatic cholangiocarcinoma.

8 ce, mortality, and survival rates of primary intrahepatic cholangiocarcinoma.

9 soforms 1 or 2 occur in approximately 15% of intrahepatic cholangiocarcinomas.

10 ehydrogenase (IDH) is recurrently mutated in intrahepatic cholangiocarcinomas.

11 tly expanded the genetic characterization of intrahepatic cholangiocarcinomas.

12 and IDH2 genes encoding metabolic enzymes in intrahepatic cholangiocarcinomas.

13 role of dysregulated chromatin remodeling in intrahepatic cholangiocarcinomas.

14 osis and most of the tumors that formed were intrahepatic cholangiocarcinomas.

15 We identified all patients with intrahepatic cholangiocarcinoma aged 65 years and older

16 ate the prevalence of known risk factors for intrahepatic cholangiocarcinoma and explore other potent

17 contrast enhancement is a typical feature of intrahepatic cholangiocarcinoma and may aid in the detec

18 ondary glioblastoma, acute myeloid leukemia, intrahepatic cholangiocarcinoma, and chondrosarcomas, le

19 cers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are leading causes of c

20 Clinicians need to be aware of intrahepatic cholangiocarcinomas arising in cirrhosis an

21 cancers including hepatocellular carcinomas, intrahepatic cholangiocarcinomas, basal cell carcinomas,

22 constitute a novel therapeutic approach for intrahepatic cholangiocarcinoma, because this protein al

23 Intrahepatic cholangiocarcinoma (CCA) is a lethal malign

24 Intrahepatic cholangiocarcinoma (CCA) is characterized b

25 e to enrich for cell surface proteins of the intrahepatic cholangiocarcinoma cell line CC-SW-1 was de

26 s inhibitor celecoxib on the growth of human intrahepatic cholangiocarcinoma cells.

27 associated with hepatocellular carcinoma and intrahepatic cholangiocarcinoma development.

28 1 activity was high throughout the course of intrahepatic cholangiocarcinomas development and low dur

29 t also produced a significant suppression of intrahepatic cholangiocarcinoma growth when administered

30 The incidence of intrahepatic cholangiocarcinoma has been recently increa

31 sociated fibroblastic cells in the stroma of intrahepatic cholangiocarcinoma has recently been demons

32 ly encompassing hepatocellular carcinoma and intrahepatic cholangiocarcinoma, has become the second l

33 primary modality of treatment for hilar and intrahepatic cholangiocarcinoma (HCCA-ICCA).

34 Seven patients had nodules demonstrating intrahepatic cholangiocarcinoma (I-CCA), nine had I-CCA

35 Intrahepatic cholangiocarcinoma (ICC) and hepatocellular

36 Curative treatment of intrahepatic cholangiocarcinoma (ICC) and hilar cholangi

37 s study aimed to estimate incidence rates of intrahepatic cholangiocarcinoma (ICC) and non-Hodgkin ly

38 on outcomes following surgical management of intrahepatic cholangiocarcinoma (ICC) are limited.

39 at mediate the initiation and development of intrahepatic cholangiocarcinoma (ICC) associated with he

40 Staging of intrahepatic cholangiocarcinoma (ICC) has historically m

41 rom combined hepatocellular liver cancer and intrahepatic cholangiocarcinoma (ICC) has increased and

42 rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in

43 We aimed to examine the burden of intrahepatic cholangiocarcinoma (ICC) in Thailand and id

44 Intrahepatic cholangiocarcinoma (ICC) is a highly malign

45 Intrahepatic cholangiocarcinoma (ICC) is a primary cance

46 PURPOSE OF REVIEW: Intrahepatic cholangiocarcinoma (ICC) is a treatment-ref

47 rgical tumor resection (R0) for treatment of intrahepatic cholangiocarcinoma (ICC) is potentially cur

48 Intrahepatic cholangiocarcinoma (ICC) is the second most

49 Intrahepatic cholangiocarcinoma (ICC) likely originates

50 st common liver cancer, can be classified as intrahepatic cholangiocarcinoma (ICC) or extrahepatic ch

51 ions between diabetes, smoking, obesity, and intrahepatic cholangiocarcinoma (ICC) risk remain inconc

52 In patients with intrahepatic cholangiocarcinoma (ICC), the oncologic ben

53 on and aggressive malignancy of mass-forming intrahepatic cholangiocarcinoma (ICC), we modeled ICC de

54 to induce hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).

55 cated a possible association between HCV and intrahepatic cholangiocarcinoma (ICC).

56 Intrahepatic cholangiocarcinoma (iCCA) is a fatal bile d

57 er comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare t

58 Intrahepatic cholangiocarcinomas (ICCs) are primary live

59 102 hepatocellular carcinomas (HCCs), three intrahepatic cholangiocarcinomas (ICCs), one neuroendocr

60 Tumor sites of origin were intrahepatic cholangiocarcinoma (IH; n = 23), hilar chol

61 ata suggesting a rising worldwide incidence, intrahepatic cholangiocarcinoma (IHC) remains an uncommo

62 Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are ineffective.

63 Intrahepatic cholangiocarcinoma (IHCC) is a primary canc

64 among the most common genetic alterations in intrahepatic cholangiocarcinoma (IHCC), a deadly liver c

65 increase in the incidence and mortality from intrahepatic cholangiocarcinoma in the United States in

66 termine recent trends in the epidemiology of intrahepatic cholangiocarcinoma in the United States.

67 Intrahepatic cholangiocarcinoma is a treatment refractor

68 The incidence of intrahepatic cholangiocarcinoma is increasing worldwide.

69 1997, the incidence and mortality rates from intrahepatic cholangiocarcinoma markedly increased, with

70 ver tumors (hepatocellular carcinoma: n = 3, intrahepatic cholangiocarcinoma: n = 2, extrahepatic cho

71 ngiocarcinoma cells in relation to promoting intrahepatic cholangiocarcinoma progression is only just

72 alk with cholangiocarcinoma cells to promote intrahepatic cholangiocarcinoma progression.

73 r-associated fibroblastic cells in promoting intrahepatic cholangiocarcinoma progression.

74 ted in an orthotopic, syngeneic rat model of intrahepatic cholangiocarcinoma progression.

75 pment of novel multitargeting strategies for intrahepatic cholangiocarcinoma therapy.

76 Intrahepatic cholangiocarcinoma typically presents in an

77 Through exomic sequencing of 32 intrahepatic cholangiocarcinomas, we discovered frequent

78 BDEsp cells yielded only small nonmetastatic intrahepatic cholangiocarcinomas without bile duct obstr